Nazanin Zanjanizadeh Ezazi1, Rubina Ajdary2, Alexandra Correia1, Ermei Mäkilä3, Jarno Salonen3, Marianna Kemell4, Jouni Hirvonen1, Orlando J Rojas2,5, Heikki J Ruskoaho6, Hélder A Santos1,7. 1. Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy , University of Helsinki , FI-00014 Helsinki , Finland. 2. Department of Bioproducts and Biosystems, School of Chemical Engineering , Aalto University , P.O. Box 16300, FI-00076 Aalto , Espoo , Finland. 3. Laboratory of Industrial Physics, Department of Physics and Astronomy , University of Turku , FI-20014 Turku , Finland. 4. Department of Chemistry , University of Helsinki , FI-00014 Helsinki , Finland. 5. Departments of Chemical & Biological Engineering, Chemistry, and Wood Science , The University of British Columbia , 2360 East Mall , Vancouver , British Columbia V6T 1Z3 , Canada. 6. Drug Research Program, Division of Pharmacology and Pharmacotherapy , University of Helsinki , FI-00014 Helsinki , Finland. 7. Helsinki Institute of Life Science (HiLIFE) , University of Helsinki , FI-00014 Helsinki , Finland.
Abstract
Heart tissue engineering is critical in the treatment of myocardial infarction, which may benefit from drug-releasing smart materials. In this study, we load a small molecule (3i-1000) in new biodegradable and conductive patches for application in infarcted myocardium. The composite patches consist of a biocompatible elastomer, poly(glycerol sebacate) (PGS), coupled with collagen type I, used to promote cell attachment. In addition, polypyrrole is incorporated because of its electrical conductivity and to induce cell signaling. Results from the in vitro experiments indicate a high density of cardiac myoblast cells attached on the patches, which stay viable for at least 1 month. The degradation of the patches does not show any cytotoxic effect, while 3i-1000 delivery induces cell proliferation. Conductive patches show high blood wettability and drug release, correlating with the rate of degradation of the PGS matrix. Together with the electrical conductivity and elongation characteristics, the developed biomaterial fits the mechanical, conductive, and biological demands required for cardiac treatment.
Heart tissue engineering is critical in the treatment of myocardial infarction, which may benefit from drug-releasing smart materials. In this study, we load a small molecule (3i-1000) in new biodegradable and conductive patches for application in infarcted myocardium. The composite patches consist of a biocompatible elastomer, poly(glycerol sebacate) (PGS), coupled with collagen type I, used to promote cell attachment. In addition, polypyrrole is incorporated because of its electrical conductivity and to induce cell signaling. Results from the in vitro experiments indicate a high density of cardiac myoblast cells attached on the patches, which stay viable for at least 1 month. The degradation of the patches does not show any cytotoxic effect, while 3i-1000 delivery induces cell proliferation. Conductive patches show high blood wettability and drug release, correlating with the rate of degradation of the PGS matrix. Together with the electrical conductivity and elongation characteristics, the developed biomaterial fits the mechanical, conductive, and biological demands required for cardiac treatment.
Entities:
Keywords:
conductive polymers; drug delivery; heart tissue engineering; polypyrrole; regeneration
Cardiovascular
diseases (CVDs) include disorders of heart and blood vessels and are
the most common cause for over 17 million deaths worldwide, as measured
only in the year 2016.[1,2] Heart failure alone affects more
than 23 million people globally and imposes a huge economic burden
on societies. Heart failure is associated with increased morbidity
and mortality and confers a substantial burden on the health-care
system. Currently available treatments for heart failure include drug
treatment, cardiac resynchronization therapy, mechanical support
devices, and heart transplantation.[3] Although
these techniques may apply for the majority of the patients and reduce
the number of hospitalization instances, the long-term prognosis of
patients with heart failure is poor. Due to the limitation of donor
heart or applicability and efficiency of drugs in specific tissues,
along with their adverse effects and thrombosis in the implant sites,[3,4] novel and advanced techniques are now at the center of attention
to reduce the burden of morbidity and mortality associated with heart
failure. In this regard, tissue engineering emerges as a promising
approach to advance cardiovascular medicine. By adopting different
materials and formulations, biomaterials can fulfill clinical needs,
such as regeneration or repair of the damaged tissue toward improved
structures and functions.[5] In fact, heart
tissue engineering (HTE) has been shown to promote the recovery of
the infarcted heart muscle after blockage of the coronary arteries.[6]Biodegradable composite patches pioneer
tissue engineering therapy. Such composites can be tailored to the
physicochemical demands for heart therapy and tissue regeneration,
including surface chemistry, electrical conductivity, and degradation
profile.[7] The composites can be applied
to the infarcted area of the heart and help the recovery, while gradually
degrading over time without any need for a secondary surgery for removal.[8,9] The biocomposites can be loaded with drugs for delivery before complete
patch degradation.[10] In such uses, the
given engineered biomaterials[11] can be
considered as carriers, including nanoparticles,[12,13] films,[14] microneedle systems,[15] and fibers.[16]We use poly(glycerol sebacate) (PGS), an elastic polyester, for the
2D heart patches. PGS is easily synthesized by the polycondensation
of nontoxic sebacic acid and glycerol, both approved by the U.S. Food
and Drug Administration (FDA) as pharmaceutical products.[17] Soft, hydrated elastic PGS is suitable for cell
culturing[17−19] and mechanically suitable for the dynamic demands[20] of the heart tissue. The physical properties
of PGS can be tailored by curing temperature and time[20,21] and can be coupled by different polymers to make a composite with
customized properties[22,23] and drug delivery profiles.[24] For example, PGS has been electrospun with gelatin
to make aligned nanofibrous webs for HTE, inducing synchronous contractions
of cardiomyocytes.[22] Collagen, the most
abundant protein in the human body[25] and
myocardium extracellular component,[26] has
been also used with PGS to induce cell attachment and proliferation,
for example, as an electrospun system for myocardial infarction applications.[25] PGS/collagen core/shell fibers developed by
Ravichandran et al. showed a high attachment of cardiomyocytes–mesenchymal
stem cells on the scaffold.[25] In addition,
PGS can incorporate a conductive polymer to endow electrical conductivity.[27] For example, polypyrrole (PPy) has been used
for diverse applications[28] owing to its
excellent cell biocompatibility[5,29] and conductivity.[29] However, due to its poor mechanical strength
and brittleness, PPy usually is combined with other polymers.[30,31]Despite the few reports on conductive PGS composites for HTE,
coupling with drug delivery systems has remained challenging. Here,
we engineer smart thin films comprising PGS used as a (elastic hydrophilic)
matrix together with collagen (for cell attachment) and PPy (for electrical
conductivity), which form a composite ideal for the myocardial infarction
application. The physicochemical properties and in vitro evaluation,
cardiomyoblast viability, and attachments are studied. (3-Aminopropyl)triethoxysilane-functionalized
thermally carbonized porous silicon nanoparticles (APTES-TCPSi NPs)[32] are attached on the surface of the conductive
composite patch to investigate the functionalization ability of the
surface. In addition, the proposed system is loaded with a model drug
3i-1000 to examine its delivery potential. The compound 3i-1000 is
a small molecule inhibitor of GATA4-NKX2-5 transcriptional synergy,
inhibiting a cardiomyocyte hypertrophic response and promoting the
myocardial repair and regeneration in experimental models of myocardial
infarction and hypertension.[33−36] We present a smart drug-loaded conductive biodegradable
patch with a surface that can be functionalized by NPs for cardiac
applications. Its easy processing and shape customizability make the
proposed smart system suitable for implantation on the surface of
the infarcted heart muscle, offering a new option for the treatment
of related conditions.
Materials and Methods
Materials
PPy, sebacic acid, and glutaraldehyde solution (25 wt % in H2O) were purchased from Sigma-Aldrich. Glycerol 85% was purchased
from Yliopiston Apteekki, Finland. Sodium dodecyl sulfate (SDS), dimethylsulfoxide
(DMSO), and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
were purchased from Sigma-Aldrich. Phosphate-buffered saline (PBS)
10×, FBS, Dulbecco’s modified Eagle medium (DMEM), l-glutamine, nonessential amino acids (NEAAs), and penicillin–streptomycin
were purchased from HyClone. Hank’s buffered salt solution
(HBSS) 10× was obtained from Gibco Life Technologies, and micro-bicinchoninic
acid (BCA) protein assay kit was obtained from Thermo Fisher Scientific.
The small molecule compound 3i-1000 was purchased from Pharmatory
Ltd. (Oulu, Finland). 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) was
purchased from abcr, Germany, and Collagen Type I, Calf Skin Lyophilized
was obtained from EPC.
Preparation of the Conductive Composite Scaffold
Composite cardiac patches were prepared from PGS, collagen, and
PPy by the evaporation method. First, pre-PGS was synthesized by the
polycondensation of an equimolar mixture of glycerol and sebacic acid.[37] Sebacic acid was weighted and moved to a clean
two-neck flask that was later closed by a plastic cap and a two-layer
balloon filled with argon gas. The remaining air inside the container
was sucked out by a vacuum system and replaced with argon gas. Then,
glycerol was added dropwise through a plastic cap by a syringe equipped
with a long flexible needle. The mixture was moved to the paraffin
oil bath at 120 °C for 24 h on a low-speed stirring. The formed
pre-PGS was dissolved in HFIP before the prepolymer viscosity was
raised, followed by the addition of 0.5% w/v (in HFIP) collagen. PPy
solutions (1 and 5% w/v [in water]) were tip-sonicated by a high-intensity
ultrasonic processor in a 40% amplitude before adding to the pre-PGS/collagen
to make a dark black color mixture.[5] The
suspension was mixed (600 rpm, 48 h) until it reached homogeneity.
The suspension was poured into a round, self-made, silicone (Zhermack
ZA22) mold (details in the Supporting Information (SI)). The HFIP was then evaporated overnight and later cured at
120 °C under a high vacuum for 48 h to obtain the elastic conductive
heart patch. In total, different types of patches were made using
different percentages of PPy and collagen: 0% collagen–0% PPy
(0C–0P); 0% collagen–1% PPy (0C–1P); 0.5% collagen–0%
PPy (0.5C–0P); 0.5% collagen–1% PPy (0.5C–1P);
and 0.5% collagen–5% PPy (0.5C–5P).
Functionalization
of the Conductive Elastic Cardiac Patch with PSi NPs
To check
the activity of the surface of the patch, hydrophilic (3-aminopropyl)triethoxysilane-functionalized
thermally carbonized porous silicon nanoparticles (APTES-TCPSi)[32] were chosen to be functionalized on the surface
of the 0.5C–5P patch. Before adding the particles on the surface
of the patch, 1 mL of N-hydroxysuccinimide (NHS)/(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride) (EDC) (10 μM) in 2-(N-morpholino)ethanesulfonic
acid MES (pH 5.5) mixture was added into each replicate at 4 °C
in an icebox. Afterward, 1 mg of APTES-TCPSi NP was added to each
solution on a shaker at 600 rpm for 12 h. The samples were washed
with water and ethanol 10 times and were dried at 37 °C. Another
set of samples were immersed in MES without cross-linkers and added
to 1 mg of the APTES-TCPSi NP solution on a shaker at 600 rpm for
12 h, followed by washing 10 times with ethanol and water and drying
at 37 °C.
Physiochemical Properties
The chemical
structure of the samples was investigated by Fourier transform infrared
(FTIR) spectroscopy, using a Vertex 70 spectrometer (Bruker Optics
GmbH) equipped with a MIRacle horizontal attenuated total reflectance
accessory (Pike Technologies Inc.) resolution of 4 cm–1.Thermogravimetry (TG) analysis of the samples was performed
with a TGA-7 (PerkinElmer Inc.) system under a N2 flush
of 200 mL min–1 using a heating ramp of 20 °C
min–1. Differential scanning calorimetry (DSC) measurements
were done with the Pyris Diamond DSC (PerkinElmer Inc.) using a heating
ramp of 10 °C min–1 with a N2 flush
of 40 mL min–1. A CAM 200 optical contact angle
meter from KSV Instruments Ltd. equipped with a CCD camera module
was used to image and calculate the wetting angle between the blood
drops on the surface after 2 s. The wetting angle was obtained by
calculating the average amount of two contact angles from both sides,
using Attension Theta software.
Conductivity
A
Jandel Model RM3000 four-point probe test unit combined constant current
source and digital voltmeter was used to measure the sheet resistance
of cardiac patches. The conductivity, C (S cm–1), was calculated using the formula C = [1/(R × t)],[31] where R is measured in units
of Ohms square–1, and t is the
film thickness in centimeters. A caliper was used to measure the thickness
of each sample, and the reported values are the average of five replications.
Mechanical Properties
The composite patches were made following
the same process as explained before by adding collagen (0.5%) and
PPy (5%) to pre-PGS at 120 °C for 24 h under low rotating speed.
The suspension was cast in the form of a dog bone shape using a silicon
(Zhermack ZA22) mold following the ASTM D638 standard (details in
the SI). The HFIP evaporated overnight,
and the prepolymer was cured at 120 °C under a high vacuum, using
a vacuum oven for 48 h. Half of the samples were detached from the
mold and immersed in 3 mL of 1× PBS (pH 7.4) for 21 days. The
samples were dried at 37 °C for 24 h. The tensile properties
were tested with a Universal Instron 4240 testing machine using a
100 N load. The test speed was 3 mm min–1, and the
gauge length was 30 mm. The tensile test samples were kept at room
temperature and in a 50% controlled humidity room for 24 h before
performing the test. The elastic modulus was calculated directly using
software.
Degradation and Swelling
The samples were cut by a
round cutter in same sizes and weighted (W0) before immersing in 3 mL of 1× PBS (pH 7.4) at 37 °C
to analyze the degradation percentage during 21 days (replicates of
three). At each time point, the samples were vacuum-dried at room
temperature for 24 h and weighed again to obtain (WD). The degradation was calculated as: degradation % =
(W0 – WD) × 100/W0.In addition, to
study the degradation speed in different media, the degradation study
was done in ethanol and 0.1 M of NaOH, and compared with 1× PBS
(pH 7.4) at 24 h. At the same time, the swelling behavior was also
studied in the same media. A round cutter was used to cut the samples
with the same size. They were weighed (W0) and immersed into 3 mL media. After 24 h, the samples were wiped
with a filter paper to absorb the medium on the surface and weighted
in a wet state (WS), and the swelling
was calculated as Swelling % = (Ws – W0) × 100/W0.
Protein Adsorption
The BCA protein assay was used to investigate
the protein adsorption (first phenomena after scaffold implantation)
on the patch surfaces. Conductive and nonconductive samples were kept
at the bottom of the 48-well plates, using a Pyrex cylinder, where
they were washed with ethanol and 1× PBS (pH 7.4). Afterward,
a 1× PBS + 10% FBS solution was added to the samples and incubated
for 4, 14, and 24 h at 37 °C to study the role of time in the
adsorption of the proteins on the surface of the cardiac patch. Loosely
attached proteins were washed away in two steps. First, a filter paper
was used to gently remove the liquid on the surface, and then the
samples were moved to a new 48-well plate and washed by 1× PBS
several times. The adsorbed protein was recovered by 2% sodium dodecyl
sulfate (SDS) and analyzed by a micro-BCA protein assay kit (Thermo
Scientific Inc.), based on the manufacturer’s protocol and
measured by a Varioskan Flash plate reader (Thermo Scientific Inc.
Fisher).
Drug Release Tests
0.5C–5P samples were prepared
by adding sonicated 5% PPy and 0.5% collagen suspensions in tetrahydrofuran
(THF)/HFIP to pre-PGS. A volume of 0.5 mL of the suspension was pipetted
out into the glass bottles, and 2 mg in 0.5 mL of 3i-1000 inside the
THF was added. THF was evaporated overnight, and the drug-loaded patches
were sintered at 120 °C for 48 h in a vacuum oven. Three samples
were sintered without loading the compound and used as controls. The
3i-1000-loaded patches were immersed in the MES solution (5 mL, pH
6) and 1× PBS (5 mL, pH 7.4), corresponding to the conditions
prevalent in infarcted heart[38] and physiological
environments; they were further incubated at 37 °C for 80 days
to check the role of pH in drug release. In addition, functionalized
APTES-TCPSi NPs on 0.5C–5P and blank 0.5C–5P surfaces
were immersed in the 2 mg mL–1 of 3i-1000 solution
for 2 h and washed one time with water and immediately immersed in
MES (pH 6) and 1× PBS (pH 7.4) to study the release of the adsorbed
and NP-loaded 3i-1000 on the surface of 0.5C–5P. At each time
point, 1 mL of the medium was replaced by an equal volume of a fresh
medium. The release study was analyzed by high-performance liquid
chromatography (HPLC) (Agilent 1260, Agilent Technologies). The HPLC
conditions were: column Gemini NX-C18 (100 × 4.6 mm2, 3 μm, Phenomenex, Denmark), a flow rate of 0.9 mL min–1, and an injection volume of 20 μL with a mobile
phase of 0.1% phosphoric acid (PA)/methanol (65:35 v/v) were
used to study the release of the model drug. The column temperature
was kept at 25 °C, and the detection wavelength used was 280
nm. The released amount of compound in each time point was calculated
by integrating the total area under the peaks of the detected 3i-1000
in each sample.
Cell Viability
The samples were
sterilized under a UV lamp for 3 h and transferred to 48-well plates,
where they were kept at the bottom of each well using Pyrex cylinders
(Thermo Fisher Scientific Inc.). To each well of the samples and the
empty well + Pyrex cylinders were added by fresh DMEM + 10% FBS and
1% (w/v) l-glutamine, 1% (w/v) NEAA, and penicillin–streptomycin
(100 IU mL–1) and stored for 24 h at 37 °C
in 5% CO2. About 10 000 cardiomyoblast rat cells
(H9c2(2-1) (ATCC CRL1446), USA) were seeded on top of each patch and
kept at 37 °C in 5% CO2. The old medium was discarded
every 2 days and was replaced by fresh DMEM + 10% FBS and antibiotics.
At each time point, AlamarBlue cell viability reagent (Thermo Fisher
Scientific) was used to analyze the cell proliferation.DMEM
+ 10% AlamarBlue was added to each well of the samples, where the
positive control were the empty well + Pyrex cylinders and the negative
control was 1% Triton X-100, and stored in an incubator for 6 h in
the dark before measuring. The fluorescent resorufin solution was
collected and moved into opaque 96-well plates, and the proliferation
was measured by a Varioskan Flash plate reader (Thermo Fisher Scientific
Inc.). In addition, prepolymer composited was cast in four replicates
of glass bottles, and to it was added 2 mg 0.5 mL–1 of 3i-1000 inside THF. Glass bottles were used to cast the prepolymer
without the compound 3i-1000 and used as control. After the solvent
evaporation and curing step in a vacuum oven, the samples were sterilized
under UV for 3 h and immersed in DMEM + 10% FBS for 24 h in the incubator
at 37 °C in 5% CO2. About 10 000 H9C2 cells
were seeded into all of the glass bottles covered by a flask cap with
a filter. At each time point, the viability of the cells was evaluated
by the AlamarBlue assay.In addition, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was utilized to examine the cytotoxicity of patch
degradation by the extract method for 21 days. Five replicates of
each UV-sterilized sample were immersed inside DMEM + 10% FBS and
1% (w/v) l-glutamine, 1% (w/v) NEAA, and penicillin–streptomycin
(100 IU mL–1) at 37 °C in 5% CO2 in 48-well plates for 28 days. At the same time, a blank control
of DMEM + 10% FBS was incubated in the same condition for 21 days.
Separately, 24 h before each time point of days 1, 7, 14, 21, and
28, about 10 000 myoblast H9C2 cells were seeded inside a fresh
medium in a 96-well plate for each type of sample, including the positive
(incubated medium) and negative (1% Triton X-100) controls. At each
time point, the medium of each well in the 96-well plates was replaced
by the medium of the incubated samples, as well as the positive (blank
medium) and negative (1% Triton X-100) controls. The well plate was
incubated for 24 h at 37 °C in 5% CO2. Next, each
well was washed twice with PBS buffer (pH 7.4), and 100 μL of
the MTT solution (0.5 mg mL–1) in HBSS–HEPES
(pH 7.4) was added and incubated in the dark for 4 h. To each sample
was added 100 μL of DMSO and kept on a shaker for 10 min.
The formazan was collected from each well into a new transparent 96-well
plate and was measured by a Varioskan Flash plate reader (Thermo Scientific
Inc.).
Cell Attachment
Cardiomyoblast morphology and attachment
were investigated on the surface of cardiac patches using a scanning
electron microscope (SEM), Hitachi S-4800. Samples were sterilized
under UV for 3 h and kept in DMEM + 10% FBS and 1% (w/v) l-glutamine, 1% (w/v) NEAA, and penicillin–streptomycin (100
IU mL–1) at 37 °C in 5% CO2 in 48-well
plates for 24 h. Near 20 000 myoblast H9C2 were seeded on the
samples that were kept at the bottom of the well using Pyrex cylinders.
After 24 h, the samples were washed twice with PBS buffer (pH 7.4)
and fixed by 2.5% glutaraldehyde in 1× PBS at 37 °C for
1 h, followed by postfixation, using 1% osmium tetroxide in PBS for
1 h. Afterward, the cells were dehydrated using different concentrations
of ethanol (50, 70, 96, and 100%). The samples were coated with 5
nm of gold–palladium alloy prior to imaging and evaluated using
an acceleration voltage of 10 kV.
Statistical Analysis
The results are expressed as mean ± standard deviations (SD)
of at least three independent sets of measurements. Statistical analysis
was done using a one-way analysis of variance (ANOVA) with the level
of significance set at probabilities of *p < 0.05,
**p < 0.01, ***p < 0.001,
analyzed with OriginPro8.6 software (OriginLab Corp.).
Results
and Discussion
To evaluate the capability of degradable heart
patch to release the model drug for HTE application, we propose the
conductive and elastic PGS-based patches loaded with 3i-1000 using
the simple casting and evaporation method. We first started by synthesizing
the conductive patch, as shown in Scheme , where the processing steps are illustrated.
Pure PGS of 0% collagen–0% PPy (0C–0P), 0% collagen–1%
PPy (0C–1P), and 0.5% collagen–0% PPy (0.5C–0P)
samples were used as control and for comparison with 0.5% collagen–5%
PPy (0.5C–5P) patches.
Scheme 1
Schematic Illustration of the Steps
Used for the Synthesis of Conductive and Elastic Biodegradable Cardiac
Patches Using the Evaporation Method
Polycondensation of
sebacic acid and glycerol was used to prepare pre-PGS, followed by
the addition of collagen type I and conductive PPy. The solvent was
evaporated, and the precomposite polymer was cured at high temperature
under vacuum.
Schematic Illustration of the Steps
Used for the Synthesis of Conductive and Elastic Biodegradable Cardiac
Patches Using the Evaporation Method
Polycondensation of
sebacic acid and glycerol was used to prepare pre-PGS, followed by
the addition of collagen type I and conductive PPy. The solvent was
evaporated, and the precomposite polymer was cured at high temperature
under vacuum.
Surface Morphology
The functionality
of the conductive patch was examined by attaching the NPs on the surface.
The surface morphology of blank, functionalized 0.5C–5P and
absorbed APTES-TCPSi NPs[32] on 0.5C–5P
was analyzed by SEM, using Hitachi S-4800. PGS, collagen, and PPy
composite formed a uniform and homogeneous structure (Figure a), which is suitable for cell
attachment and functionalization. APTES-TCPSi NPs were functionalized
and adsorbed on 0.5C–5P and formed a rough surface, as shown
in Figure b,c, respectively.
The functionalized and adsorbed NPs on the surface of the composite
were confirmed by energy-dispersive X-ray spectroscopy (EDX) (Figure S1a). The physical adsorption without
cross-linkers could not show an efficient NP attachment, and the NPs
were easily detached during the washing steps by water and ethanol
(Figure c). Due to
the hydroxyl and carbonyl groups on the surface of the patch (Figure S1b), NPs can be functionalized using
NHS and EDC chemistry to facilitate coupling via amidation.[39] NPs coupled on the surface retained their morphology
(Figure b) and remained
stable after washing. FTIR spectra show the hydroxyl (−OH)
stretching bond around 3500 cm–1 and the ester bonds
of (C=O) at 1730 cm–1, which is due to the
carbonyl stretching vibration. The stretching (−CH2) is shown at 2850, and 2925 and 1169 cm–1, representing
the C–O–C stretching peak. The amides I and II of collagen
(around 1638 and 1554 cm–1)[25,31,40,41] and PPy bands
of the bending and stretching of amine groups (1560 and 880 cm–1)[31] are properly masked.
These active groups on the surface of the PGS matrix suggest the high
potential of the surface for functionalization with the amine-terminated
PSi NPs.
Figure 1
Surface morphology (SEM) of (a) blank 0.5C–5P, (b) 0.5C–5P
functionalized with APTES-TCPSi NPs, and (c) 0.5C–5P carrying
adsorbed APTES-TCPSi NPs, without cross-linking. The scale bars correspond
to 100 μm (top) and 3 μm (bottom).
Surface morphology (SEM) of (a) blank 0.5C–5P, (b) 0.5C–5P
functionalized with APTES-TCPSi NPs, and (c) 0.5C–5P carrying
adsorbed APTES-TCPSi NPs, without cross-linking. The scale bars correspond
to 100 μm (top) and 3 μm (bottom).
Physicochemical Characterization
TG and DSC were used to
compare the thermal properties of the composite and pure PGS. Both
methods show that the thermal properties of the composite patch of
0.5C–5P are similar to those of the pure PGS (Figure S1c). Both 0.5C–5P composite and pure PGS (0C–0P)
degrade nearly completely, with the degradation starting at ca. 465
°C, leaving behind ca. 1–2 wt % of residue. The DSC results
show that there are no phase transitions occurring below 200 °C,
with the broad endotherm below 110 °C appearing as drying of
the sample. In general, the addition of collagen and PPy to the PGS
matrix did not appear to change the thermal properties of PGS.In addition, the crystallinity and TGA/DSC analysis of pure 3i-1000
(Figure S4a,b) were done to check the stability
of the compound. The XRD confirmed the initial crystallinity of the
pure drug, with the DSC results showing only one endothermic peak
after 120 °C, corresponding to the melting of 3i-1000 crystals.
Moreover, the wettability was studied by both qualitative and quantitative
methods (Figure S2). After the implantation
of the biomaterials inside the body, proteins and blood will cover
the surgery area.[42] As a result, the blood
wettability test was done to study the wetting behavior of patches
inside the human blood (obtained from anonymous donors from the Finnish
Red Cross). Conductive and pure PGS patches (around 10 mm in diameter)
were immersed in 3 mL of blood in sterile conditions and pictured
after 5 s and 48 h. First, 0C–0P and conductive patches of
0.5C–5P were sterilized and immersed in 1 mL of blood for 5
s, and the wetting ability was observed. The same samples were immersed
in blood for 48 h inside the incubator at 37 °C in 5% CO2. The samples were washed twice with water and again immersed
in blood samples, and the wettability was observed again.The
results showed that the conductive composite containing 5% of PPy
has higher blood wettability compared with the pure PGS at two different
time points. However, the quantitative results show the same range
of contact angle of θ = 59.35° ± 12.2 for 0C–0P
and θ = 55.51° ± 4.9 for 0.5C–5P, which is
due to the O–H group[40] on the pure
PGS, showing its hydrophilic properties. The qualitative image results
are due to the PPy, the hydrophobic characteristics of which[41] make the composite more hydrophobic compared
with the pure PGS. It has been reported that the hydrophobic surfaces
are able to adsorb protein C3, fibronectin, and vitronectin to a greater
extent compared with the hydrophilic surfaces. In addition, platelets
and leukocytes in blood have higher absorbance in the hydrophobic
samples.[42,43] Platelets are attached to the hydrophobic
surfaces after 5 s,[42,43] which can help to wet the PPy-based
composite more than PGS.In tissue engineering
applications, adequate electrical conductivity is essential in composites
to guarantee an efficient signal transfer to cells. The conductivity
properties were tested by a four-point probe system. PPy is a highly
conductive, stable, and biocompatible polymer that has been applied
for biosensors, antioxidants, drug delivery, and tissue engineering
applications.[44] The conductivity of PPy-containing
composites is highly dependent on the synthesis method and the concentration
of the conducting polymer.[45] For example,
Yang et al. reported that the composition of 1% hyaluronic acid solution
with 50 mM of PPy resulted in the conductivity of 7.3 mS cm–1,[46] while cellulose/PPy[47] and agarose/PPy[48] composites
showed conductivities of 0.08 and 0.1 S cm–1, respectively.
In our study, the concentration of 1% PPy did not provide a well-dispersed,
homogeneous electrical conductivity along with the films and resulted
in partial conductive samples, while increasing the concentration
of PPy to 5% facilitated a better chance for conductive chains of
polymers to entangle more effectively in the same processing method
(Table ), showing
a conductivity of 0.06 S cm–1, which is higher compared
with a similar system already reported elsewhere.[31]
Table 1
Conductivity of Various Ratios of the 2D
Cardiac Patch
sample
C (S cm–1)
0C–0P
0
0.5C–0P
0
0C–1P
partial conductivity 0.009–0.011
0.5C–1P
0
0.5C–5P
0.06 ± 0.14
Mechanical
Properties
The mechanical properties of cardiac patches were
tested using the Universal Instron 4240 testing machine, and the mechanical
behavior of the conductive composites was compared with that of pure
PGS before and after incubation in 1× PBS (pH 7.4) during 21
days. Figure a shows
the mechanical behavior after incubation in the buffer solution. The
cross-linking of ester bonds in the PGS backbone forms a 3D network
of random coils of thermoset, which has a rubber-like elastic behavior.
This behavior makes PGS an ideal polymer for soft tissues in dynamic
mechanical environments, such as the cardiovascular systems.[49] The mechanical properties of PGS are directly
associated with the degree of cross-linking and are easily tunable
by altering the curing time. The PGS showed an elastic modulus of
0.17 MPa with the curing times of 48 h, which is comparable with other
references.[50] The elastic modulus of PGS
ranges between 0.05 and 1.5 MPa as reported by Chen et al.[50] PPy is known to change the mechanical properties
of composites and hydrogels significantly due to its poor mechanical
properties and heterogeneous distribution in the polymer matrix.[51] The presence of PPy in a minor ratio in the
PGS matrix alters the properties slightly (Table ). The mechanical properties changed after
immersion in 1× PBS, and both types of the samples showed higher
elongation (Figure a).
Figure 2
(a) Mechanical stress–strain curve of dry and incubated 0C–0P
and 0.5C–5P composites in 1× PBS (pH 7.4) for 21 days.
(b) Degradation percentage of 0C–0P, 0C–1P, 0.5C–0P,
and conductive 0.5–5P during 21 days. Statistical analysis
was achieved by means of a one-way analysis of variance (ANOVA), with
the level of significance set at probabilities of **p < 0.01 and ***p < 0.001.
Table 2
Mechanical Properties of the Samples Before and After
PBS
sample
modulus (MPa)
0C–0P
0.17
incubated 0C–0P
0.17 ± 0.01
0.5C–5P
0.14 ± 0.04
incubated
0.5C–5P
0.08
(a) Mechanical stress–strain curve of dry and incubated 0C–0P
and 0.5C–5P composites in 1× PBS (pH 7.4) for 21 days.
(b) Degradation percentage of 0C–0P, 0C–1P, 0.5C–0P,
and conductive 0.5–5P during 21 days. Statistical analysis
was achieved by means of a one-way analysis of variance (ANOVA), with
the level of significance set at probabilities of **p < 0.01 and ***p < 0.001.
Degradation
The
degradation speed is a critical factor in the biodegradable composite
as it controls the stability of the biomaterials and the drug-releasing
process.[52] In our study, the degradation
of all types of samples is in the same range, indicating that the
addition of 5% PPy does not change the degradation speed of the patch.
The composite patches were degraded in a buffer of around 8% for 21
days, which can prevent the drug burst release (Figure b). In addition, the degradation and swelling
percentage were tested in ethanol and 0.1 M of NaOH and compared with
PBS in 24 h of incubation (Figure S3a).
The results show that ethanol and NaOH had higher swelling, with the
structure swelling more in ethanol compared with that in NaOH; the
addition of collagen and PPy up to 5% increased the swelling in NaOH
in the same range as in ethanol. Although ethanol swells the structure
more, the degradation is less compared with the degradation in NaOH,
which is more than 20% (Figure S3b).Protein adsorption was tested by the
BCA protein assay at three different time points of incubation of
samples with fetal bovine serum (FBS) to quantify the adsorbed protein
on the surface of the patches. Figure a shows that the time of incubation did not influence
the concentration of the adsorbed proteins, and the saturated amount
of the protein is reached at the first time point, at 4 h. However,
at 24 h of incubation of the conductive sample in the FBS solution,
the protein concentration increases from 35% to more than 40%, when
compared with 14 h. In general, the conductive patches show a higher
potential to attract proteins, which can be due to the high percentage
of hydrophobic PPy.[5]
Figure 3
(a) Protein adsorption
on 0C–0P, 0C–1P, 0.5C–0P, and 0.5C–5P
patch surfaces at three different time points of incubation of the
conductive and control patches. (b) Cumulative 3i-1000 release percentage
from the bulk of degradable conductive patch of 0.5C–5P in
1× PBS (pH 7.4) and MES (pH 6). (c) Cumulative release in the
MES buffer (pH 6) of 3i-1000 drug initially adsorbed on the surface
and loaded in functionalized APTES-TCPSi NPs. Statistical analysis
was obtained using a one-way analysis of variance (ANOVA), with the
level of significance fixed at probabilities of **p < 0.01 and ***p < 0.001.
(a) Protein adsorption
on 0C–0P, 0C–1P, 0.5C–0P, and 0.5C–5P
patch surfaces at three different time points of incubation of the
conductive and control patches. (b) Cumulative 3i-1000 release percentage
from the bulk of degradable conductive patch of 0.5C–5P in
1× PBS (pH 7.4) and MES (pH 6). (c) Cumulative release in the
MES buffer (pH 6) of 3i-1000 drug initially adsorbed on the surface
and loaded in functionalized APTES-TCPSi NPs. Statistical analysis
was obtained using a one-way analysis of variance (ANOVA), with the
level of significance fixed at probabilities of **p < 0.01 and ***p < 0.001.
Drug Release Studies
The release of the small molecule compound
3i-1000 from the bulk of the conductive patch is shown in two different
buffers, of MES (pH 6) and PBS (pH 7.4), in Figure b. No burst compound release was observed,
as the release is based on the degradation of the PGS matrix. PGS
degradation can be controlled by changing the sintering parameters,
such as curing temperature and time. Here, the temperature and duration
of curing was 120 °C in 48 h, which led to the degradation of
8% in 21 days, resulting in the release of more than 20% of the 3i-1000.
The compound release increased over time, which is due to the higher
degradation percentage of the patch until 80 days. No significant
differences were observed in the release of the 3i-1000 in the two
different buffers.The release of adsorbed 3i-1000- and 3i-1000-loaded
APTES-TCPSi NPs functionalized on the surface of 0.5C–5P was
also studied in MES (pH 6), Figure c. The compound physioadsorption efficiency was 12.59
± 2.08 for the adsorbed 3i-1000, and the encapsulation efficiency
(EE %) was 13.47 ± 1.96 for the APTES-TCPSi NP-functionalized
patch. The drug release behaviors observed for both systems were similar,
showing less than 10% of the cumulative release during 70 days in
the MES buffer (pH 6). The results indicate the minor role played
by the NPs on loading and the likelihood that 3i-1000 was mainly adsorbed
on their surface. Based on Figure b, the attached NPs are integrated with the composite
matrix and introduce a slightly higher encapsulation efficiency compared
with that of the physically adsorbed counterpart, which points to
the effect of the surface in the active matrix.Cardiomyoblast H9C2 viability was tested during 28 days using the
MTT assay to evaluate the cytotoxicity of the cells in a medium containing
degraded 2D patches. Figure a shows the viable cells and the proliferation in the degraded
medium compared with those in the blank incubated medium. This proliferation
stays in the same range for 28 days, which shows the biocompatibility
of the patch during almost a month. In addition, the AlamarBlue assay
shows that the proliferation of the cells increased during 21 days,
and the cell number doubled during a week from day 14 until day 21.
It can be seen in Figure b that the proliferation of the cells on the conductive samples
is higher compared with that on the pure PGS samples. In addition,
the compound 3i-1000-loaded patches were studied separately and compared
with the noncompound-loaded samples (Figure c). The results show that the 3i-1000 release
during 21 days could help the cells to proliferate (AlamarBlue assay)
compared with the samples without the compound. Based on the degradation
and release experiments, there was ca. 8% of patch degradation and
20% of compound release, which could increase the viability of the
cells and increase cell proliferation. Karhu et al.[33] previously showed that the 3i-1000 with a concentration
higher than 10 μM showed toxicity in the H9C2 cell line. Although
3i-1000-loaded patches also show toxicity on day 1, 3i-1000 could
induce the proliferation for 21 days. This system suggests that the
slow release of 3i-1000 from the system is able to provide a safe
environment for the cardiomyoblast cells in long-term applications.
Figure 4
(a) Cytotoxicity
of biodegradable patches prepared by the extract method during 28
days in DMEM + 10% FBS. (b) Proliferation of the cardiomyoblast on
the surface of the conductive biocomposite during 21 days in DMEM
+ 10% FBS. (c) Cell viability of 3i-1000 loaded inside the conductive
patch compared with the samples without the compound during 21 days.
(a) Cytotoxicity
of biodegradable patches prepared by the extract method during 28
days in DMEM + 10% FBS. (b) Proliferation of the cardiomyoblast on
the surface of the conductive biocomposite during 21 days in DMEM
+ 10% FBS. (c) Cell viability of 3i-1000 loaded inside the conductive
patch compared with the samples without the compound during 21 days.Early cell attachment
was also monitored after 24 h of seeding on the surface of the conductive
and nonconductive patches in DMEM–10% FBS. Cells expanded on
the surface of all types of samples and showed infiltration (Figure ). While there was
a higher number of cells attached on the conductive samples, higher
infiltration was observed in the samples containing collagen. In samples
containing collagen and PPy, both great cell attachment and cell infiltration
were observed. The conductive patches containing collagen have a high
potential to host the cells in the first hours after encountering
with the cells, as they can attach and expand on the surface, as well
as stay viable based on proliferation results (Figure a,b).
Figure 5
Cardiomyoblast cell attachment on the
surface of (a) 0C–0P, (b) 0C–1P, (c) 0.5C–0P,
and (d) 0.5C–5P patches on the control and conductive samples
during 24 h. Cells were expanded on all samples with high infiltration
in the collagen-containing patches. 0.5C–5P attachment shows
both high infiltration and attachment within 24 h. Scale bar represents
100 μm.
Cardiomyoblast cell attachment on the
surface of (a) 0C–0P, (b) 0C–1P, (c) 0.5C–0P,
and (d) 0.5C–5P patches on the control and conductive samples
during 24 h. Cells were expanded on all samples with high infiltration
in the collagen-containing patches. 0.5C–5P attachment shows
both high infiltration and attachment within 24 h. Scale bar represents
100 μm.
Conclusions
In
this study, a drug-loaded conductive biodegradable cardiac patch was
developed by the evaporation method. The patch showed excellent cardiomyoblast
biocompatibility with high potential for protein and cell attachment
in the early hours. The combination of collagen and PPy made a suitable
matrix for cells to be attached and infiltrated. Cells were able to
proliferate with compound-loaded patches for 21 days compared with
the noncompound-loaded patches, demonstrating the ability of this
system to deliver the model drug 3i-1000 for cell proliferation. The
drug release was based on the degradation of the patch that prevented
the burst release. The PPy-based patch showed excellent tensile properties
with high elongation, which can even be improved in a wet state suitable
for the heart patch implantation condition. The conductive patches
show good conductivity, which is important for protein adsorption,
wettability, and cell proliferation, compared with the nonconductive
samples. Overall, the conductive patches presented here are a smart
system for the myocardial infarction applications, based on the combination
of PPy, collagen, and PGS with the simultaneous drug-releasing potential.
Authors: Mika J Välimäki; Marja A Tölli; Sini M Kinnunen; Jani Aro; Raisa Serpi; Lotta Pohjolainen; Virpi Talman; Antti Poso; Heikki J Ruskoaho Journal: J Med Chem Date: 2017-09-15 Impact factor: 7.446